ABSTRACT
@#Nosocomial infections significantly contribute to a patient’s morbidity and mortality, increasing healthcare costs. While previous research has assessed the effect of oral hygiene on the prevention of nosocomial infections and postoperative complications, few guidelines exist that offer evidence-based recommendations on pre- or peri-operative oral hygiene in the surgical setting. The Philippine Surgical Infection Society set out to develop a set of guidelines that provide evidencebased recommendations on oral hygiene for improving surgical outcomes for adoption in the Philippines. Six clinical questions defined the scope of the guidelines. A systematic review was performed to provide the evidence base to develop the recommendations. A consensus meeting participated by 15 representatives from 13 specialty surgical societies and societies concerned with infection control was conducted using the modified Delphi technique to finalize the set of recommendations. A consensus guideline with sixteen recommendations on the use of oral hygiene to improve surgical outcomes is presented for adoption and implementation.
ABSTRACT
<p><b>INTRODUCTION</b>Stenotrophomonas maltophilia is an emerging pathogen in nosocomial infections that may result in high mortality. S. maltophilia often present as part of a polymicrobial culture and it is not well established when treatment is indicated. We aimed to identify predictors of mortality in patients with positive cultures of S. maltophilia.</p><p><b>MATERIALS AND METHODS</b>A retrospective cohort study in a tertiary care medical centre was performed in 150 adult patients with positive cultures of S. maltophilia. Patients' demographics, underlying diseases, severity of illness, length of hospitalisation, prior antibiotic exposure, number/types of indwelling catheters, culture sites, and appropriateness of empiric therapy were collected. Logistic regression was used to determine the independent risk factor(s) for infection-attributed mortality.</p><p><b>RESULTS</b>Ninety-nine males and 51 females were studied. The mean (SD) age and APACHE II score of the patients were 61.9 (16.0) and 14.0 (6.1), respectively. The respiratory tract was the most frequent site (55.3%) where S. maltophilia was isolated. Infection-attributed mortality was observed in 22 of the 150 patients (14.7 %). Admission to ICU [Odds ratio (OR), 3.767; 95% confidence interval (CI), 1.277-11.116, P = 0.016], and delayed effective treatment (OR, 18.684; 95% CI, 4.050-86.188; P <0.001) were identified as independent risk factors for mortality.</p><p><b>CONCLUSIONS</b>Predictors of mortality in patients with positive cultures of S. maltophilia were identified, which may guide clinicians in patient assessment and devising therapeutic decisions. Further studies are needed to validate our results.</p>
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , APACHE , Anti-Infective Agents , Therapeutic Uses , Cohort Studies , Confidence Intervals , Cross Infection , Drug Therapy , Mortality , Gram-Negative Bacterial Infections , Drug Therapy , Mortality , Intensive Care Units , Logistic Models , Odds Ratio , Predictive Value of Tests , Respiratory System , Microbiology , Retrospective Studies , Risk Factors , Singapore , Epidemiology , Stenotrophomonas maltophilia , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination , Therapeutic UsesABSTRACT
<p><b>INTRODUCTION</b>Polymyxins have become the drug of choice for treatment of multidrug-resistant gram-negative bacilli infections in Singapore, simply because these pathogens are only susceptible to either aminoglycosides and polymyxins, or polymyxins only. Furthermore, there is no new antibiotic in the pipeline that targets these difficult-to-treat infections.</p><p><b>MATERIALS AND METHODS</b>All published literatures (up to end of February 2008) regarding polymyxins are included for review.</p><p><b>RESULTS</b>This review serves to give a summary of polymyxins from the current available literature, highlighting relevant clinical studies and information that help to guide informed prescription of polymyxins, should the need arise.</p><p><b>CONCLUSIONS</b>However, there are substantial information gaps that needed to be filled urgently, to preserve the clinical utility of this very last line of antibiotic.</p>
Subject(s)
Humans , Anti-Bacterial Agents , Pharmacology , Therapeutic Uses , Drug Resistance, Multiple, Bacterial , Gram-Negative Bacteria , Gram-Negative Bacterial Infections , Drug Therapy , Microbiology , Microbial Sensitivity Tests , Polymyxins , Pharmacology , Therapeutic Uses , SingaporeABSTRACT
La eficacia y seguridad de sulbactam/cefoperazona fue evaluada en un estudio multicéntrico, abierto, no comparativo, usado como monoterapia. Doscientos dieciseis pacientes entraron inicialmente al estudio, siendo excluidos 42, por haber recibido antibioticoterapia concomiante. Ciento setenta y cuatro pacientes adultos (99M, 75 F), con rango de edad de 13 a 83 años fueron tratados con sulbactam/cefoperazona como monoterapia, en proporción 1:2, vía endovenosa, presentando 102 (59 por ciento) pacientes infecciones severas, y, 72(41 por ciento) infecciones moderadas. La localización de las infecciones fueron: piel y tejidos blandos (n=54,31 por ciento), abdominales (n=54,31 por ciento), infecciones respiratorias bajas (n=40,23 por ciento), tracto biliar (n=9,5 por ciento), tracto urinario (n=9,5 por ciento), área ginecológica (n=3,2 por ciento) y otras (n=5,3 por ciento). Ciento sesenta y uno (93 por ciento) de las infecciones fueron agudas, nueve (5 por ciento) crónicas y, 4 (2 por ciento) recurrentes. Los gérmenes obtenidos con mayor frecuencia el cultivo inicial fueron P. aeruginosa (27,16 por ciento), E.coli (n=23,13 por ciento), E.cloacae (n=14,8 por ciento), S. aureus (n=7,4 por ciento). La dosis diaria administrada de sulbactam/cefoperazona osciló entre 3 y 9 gr/día (media 4,6g/día), durante 1-70 días (media 10 días). Ciento cuarenta y cuatro pacientes fueron evaluados clínicamente, obteniéndose curación en 112 pacientes (78 por ciento), mejoría en 24 (17 por ciento), y falla en 8 pacientes (5 por ciento). Se incluyeron 96 pacientes para evaluación bacteriológica, reportándose erradicación en 88 (91 por ciento) y, persistencia en 8 (9 por ciento). Se presentaron efectos adversos en 9 pacientes (5 por ciento): rash, prolongación del PTT, cefalea, escalofríos y diarrea. Con un 95 por ciento de respuesta clínica satisfactoria, 91 por ciento de erradicación bacteriológica y buena tolerancia concluimos que sulbactam/cefoperazona usado como monoterapia es una buena elección para el tratamiento de infecciones moderadas y severas.